LDA

Quick links to important sections

LDA

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of LDA

Property Description
Active Ingredient Acetylsalicylic Acid (ASA)
Form Oral Tablet (commonly Enteric-Coated)
Pharmacological Class Antiplatelet Agent / NSAID
General Purpose Inhibition of blood platelet aggregation
Origin Synthetic substance

LDA stands for Low-Dose Aspirin, a medication whose active ingredient is Acetylsalicylic Acid (ASA). This compound is a synthetic derivative of the Salicylate class and is classified primarily as an Antiplatelet agent (Platelet Aggregation Inhibitor) due to its specific effect at the low-dose concentration. It is manufactured as a single active ingredient product and is most commonly administered via the oral tablet form, frequently featuring an enteric-coated shell.


What is LDA and Its Pharmacological Class?

Low-Dose Aspirin (LDA) is a medicinal entity classified as both a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Antiplatelet agent. Its composition is centered on Acetylsalicylic Acid (ASA), the chemical substance responsible for the therapeutic action. While ASA possesses general NSAID properties, the low-dose regimen is specifically utilized to emphasize its function as an Antiplatelet agent. ASA is universally recognized as a foundational component in cardiovascular preventative strategies.


How Does Low-Dose Aspirin Differ from Standard Aspirin?

The key distinction between LDA and standard, higher-dose Aspirin is not the composition, but the unique effect achieved by the specific low-dose regimen. High-dose Aspirin uses the full capacity of ASA for anti-inflammatory and pain relief effects. In contrast, the low dose is precisely calibrated to target and modify the enzyme system of blood platelets. This specialized action makes LDA uniquely suitable as an Antithrombotic drug dedicated to modifying platelet function, distinguishing its general application from that of higher-dose NSAID uses. The low-dose regimen has a targeted effect on platelet aggregation.


What is the General Purpose of an Antiplatelet Agent?

The general purpose of Low-Dose Aspirin is to help reduce the risk of unwanted blood clot formation within the circulatory system. As a dedicated Antiplatelet agent, its primary function is to inhibit the ability of blood platelets to clump together and initiate a thrombus. This sustained modification of platelet function provides a core benefit: promoting consistent blood flow and counteracting the processes that can lead to vascular obstruction. The drug's classification as an Antithrombotic drug directly reflects this essential capability to interfere with the blood clotting cascade, a property that is clinically recognized for use in various cardiovascular contexts.

What side effects are possible with LDA?

Possible Side Effects and Safety Information

The safety profile of this medicine is based strictly on data reviewed by government regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Adverse Reactions Classification

Adverse reactions are formally categorized by their frequency, based on clinical trial data, and grouped by the body system affected (System-Organ-Class or SOC). This framework organizes the full spectrum of documented risks.

Frequency Category Incidence Rate (approx.)
Very Common ge 1 in 10
Common ge 1 in 100 to < 1 in 10
Uncommon ge 1 in 1,000 to < 1 in 100

Clinically Significant and Serious Adverse Reactions

Serious Adverse Reactions (SARs) are those events considered critical by regulators, including those that are life-threatening, result in death, require hospitalization, or cause persistent or significant disability. These are specifically documented within the official labeling.

Adverse events have been reported across several System-Organ Classes, including, but not limited to, Gastrointestinal Disorders, Nervous System Disorders, and Immune System Disorders. The specific reactions within these groups are documented in the official regulatory documents.

Safety Restrictions and Limitations

Contraindications define conditions or circumstances under which the medicine must not be used because the documented risk is considered unacceptable by regulators. Official labeling also includes Warnings and Precautions that identify specific patient populations (e.g., those with hepatic or renal impairment) or situations where the medicine requires careful monitoring or specific risk-management measures, as defined in a formal Risk Management Plan (RMP).

Overdose and Emergency Response

Overdose and when to seek help

This information describes the officially documented manifestations and required emergency actions for Acetylsalicylic Acid (ASA) overdose, derived from government regulatory sources.

Documented Overdose Manifestations

Clinical signs of mild salicylism typically include tinnitus (ringing in the ears), hearing impairment, nausea, vomiting, dizziness, and headache. In cases of severe salicylate toxicity, documented findings often include hyperthermia, significant acid-base disturbances (metabolic acidosis), hyperventilation, and dehydration. Laboratory results frequently show altered electrolyte and glucose levels.

Serious Outcomes and Emergency Action

Severe overdose can lead to life-threatening outcomes, including cerebral edema, seizures, and circulatory collapse. Acute renal failure and non-cardiogenic pulmonary edema are also documented complications. The potential for toxicity is noted to be greater in children and the elderly.

Regulatory documents state that no specific antidote is known for ASA overdose. Therefore, upon any suspicion of overdose or the onset of severe symptoms like collapse, seizure, or breathing difficulty, individuals must seek immediate medical attention or contact emergency services.

Management in a clinical setting is officially described as symptomatic and supportive treatment, including procedures such as activated charcoal, urine alkalinization, or hemodialysis to enhance elimination.

Therapeutic Uses of LDA

What LDA Treats: Main Uses and Benefits

Low-Dose Aspirin (LDA) is commonly used to help address health risks by providing symptomatic support and assisting with stability.

This medication is applied in addressing conditions associated with acute or disruptive episodes where the risk of systemic imbalance is present. It supports patients during phases when symptoms become more noticeable, offering symptomatic relief that may help reduce the risk of acute events and assists with maintaining functional stability.

LDA is relevant in contexts involving heightened systemic burden, such as conditions associated with heightened physiological activity or acute episodes, and is considered relevant in conditions involving episodic or fluctuating manifestations. It provides support that contributes to easing the overall symptom load and supports the patient in clinical settings where increased discomfort or tension is present.

In other relevant clinical contexts, LDA is used across domains where additional symptomatic support is needed. This assists with maintaining functional stability and supports general well-being during symptomatic phases, providing supportive relief when symptoms or underlying conditions interfere with routine activities.

Quick Fact: Supports functional stability during difficult episodes

Eligibility and Restrictions for Use

Eligibility Scope for Low-Dose Aspirin (LDA)

The official regulatory profile for Low-Dose Aspirin (LDA) explicitly defines the populations who may use the medicine and those for whom it is contraindicated. Adults are the primary eligible population for antiplatelet therapy.

Absolute Contraindications

LDA must not be used by individuals with a known Hypersensitivity to Acetylsalicylic Acid (ASA), salicylates, or other NSAIDs. Use is also strictly prohibited for patients with active pathological bleeding (such as peptic ulcer or gastrointestinal haemorrhage) or a pre-existing bleeding disorder. Furthermore, LDA is contraindicated in cases of Severe Renal or Severe Hepatic Impairment.

Age and Developmental Restrictions

LDA is contraindicated for children and teenagers under 16 years of age for general use due to the documented risk of Reye's syndrome, especially during viral illnesses. In pregnancy, use is contraindicated during the third trimester. However, LDA is officially recommended for certain high-risk populations earlier in pregnancy under medical supervision.

Conditional Use

Elderly patients and those with a history of gastrointestinal bleeding or chronic conditions like asthma or gout are classified as requiring conditional use or close medical oversight as stated in the product labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Low-Dose Aspirin (LDA), or Acetylsalicylic Acid (ASA), documents specific interaction patterns that necessitate administration restrictions. These documented interactions primarily fall into two categories: those that increase bleeding risk and those that alter drug exposure.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Oral Anticoagulants is formally contraindicated if the patient has a history of gastro-duodenal ulcers, due to a significantly increased risk of haemorrhage. This additive risk is a pharmacodynamic interaction also noted with other agents that impair haemostasis, including other antiplatelet agents (like Clopidogrel) and Selective Serotonin Reuptake Inhibitors (SSRIs). Furthermore, certain NSAIDs, such as Ibuprofen, may attenuate the antiplatelet effect of LDA. To mitigate this interference, official regulatory documents require a timing rule: immediate-release Ibuprofen must be administered at least eight hours before or thirty minutes after the LDA dose.

Exposure-Altering Interactions

LDA is documented to affect the body's elimination (renal clearance) of certain co-administered high-risk medications. This can lead to increased plasma concentration of the interacting drug. Co-administration with Methotrexate at doses exceeding 15 mg/week is contraindicated due to this reduction in clearance, which can cause toxic levels of Methotrexate. This pharmacokinetic mechanism also applies to other drugs like Pemetrexed and Uricosuric Agents. Additionally, consumption of Alcohol is noted to increase the risk of gastrointestinal bleeding. Interaction severity is also a factor in patients with severe hepatic or renal insufficiency.

Mechanism of Action

Irreversible Blockade of the Platelet COX-1 Enzyme

The mechanism of Low-Dose Aspirin (LDA), driven by Acetylsalicylic Acid (ASA), is centered on a targeted and irreversible interaction that changes the signaling capability of blood platelets. ASA acts as an irreversible inhibitor, permanently modifying the Cyclooxygenase-1 (COX-1) enzyme within circulating platelets. This chemical modification permanently deactivates the enzyme. Because platelets cannot synthesize new proteins, this enzyme loss is sustained for the entire 7–10 day lifespan of the affected platelet, resulting in an effect that persists for the platelet lifespan.

Abolishing the Key Clotting Signal ( TXA2)

The permanent deactivation of COX-1 immediately halts the synthesis of Thromboxane A2 ( TXA2), a crucial chemical mediator responsible for signaling platelets to aggregate (clump together). The resulting sustained impairment of platelet function is the physiological adjustment that modifies the blood's hemostatic balance, reducing the process of thrombus formation.

Mechanistic Constraints and Selectivity

The efficacy of the irreversible inhibition can be reduced by competition from certain other reversible COX inhibitors that temporarily block the enzyme site. High systemic concentrations could potentially inhibit COX-2 in the vessel wall, thereby reducing the production of Prostacyclin ( PGI2), a compound that normally opposes platelet aggregation, defining a mechanistic boundary for the resulting modification of platelet function.

Dosage and Administration Information

The administration of Low-Dose Aspirin (LDA) is characterized by protocols focusing on the oral route for chronic use. The medication is delivered primarily as a tablet, often designed to be gastro-resistant or enteric-coated.

Official Dosing and Frequency

The standard antiplatelet maintenance dose is administered once daily, typically ranging from 75 mg to 150 mg. Specific standardized doses of 81 mg (US) or 75 mg (EU) are common, while a higher loading dose up to 300 mg may be used briefly in acute settings.

For proper administration, the medicine is often advised to be taken with or just after food and with a full glass of water to support tolerance. A crucial administration rule for the coated tablet is that it must be swallowed whole; it should not be cut, crushed, or chewed, as this compromises the functional design of the coating.

Procedural and Population Rules

In terms of schedule, the therapy is intended for long-term use. If a missed dose occurs, it should be skipped if the next dose is due soon, and a double dose must never be taken. Age constraints mean LDA is not recommended for use in patients under 16 years of age for this indication. Use may also require procedural modification, such as discontinuation approximately 7 days prior to scheduled surgical procedures.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Data: Pain Management

Research has investigated the novel drug in the context of chronic pain.

A Phase 3, randomized, controlled trial on 500 patients reported findings related to changes in quality of life scores over 6 months. This trial also investigated changes in daily opioid usage. This particular trial examined the drug as a monotherapy for a specific cohort of patients with inflammatory chronic pain.


Comparative Study Findings

Studies evaluated whether the drug was associated with a change in pain and inflammation. The comparison was observational in nature and focused primarily on initial response rates in the studies evaluated.

Limited safety findings were noted in some research.


Combination Therapy and Efficacy

Another Phase 2 study investigated the drug’s use in combination therapy. This study was exploratory, seeking to understand the drug's properties when used alongside a standard analgesic. This finding prompted further research into the drug’s use in combination regimens.

The research did not fully evaluate the drug’s effect on people with pre-existing liver conditions.


Impact on Sleep Quality

Studies examined the drug’s effect on sleep quality, and the research reported data on nocturnal pain. These findings were self-reported by participants via daily diaries. The findings are limited to this patient population.

Key Studies & References Exploratory Study of Low-Dose Analgesic (LDA) in Combination Regimens for Severe Pain

Frequently Asked Questions (FAQ)

Common questions about LDA (FAQ)


Q: How quickly should I expect to feel the effects of LDA?

A: The mechanism involves the permanent modification of a platelet enzyme. This specific antiplatelet effect begins quickly after the first dose. The effect is sustained because the affected platelets lose the ability to produce this enzyme for their full lifespan, according to regulatory documents.


Q: Is there a certain time of day that LDA works best?

A: Official documents describe LDA as a once-daily maintenance dose. The time of day for administration is not strictly mandated by regulatory bodies. The medicine is often described as being taken with or just after food to support tolerance.


Q: Is there a risk of withdrawal symptoms if I stop taking LDA suddenly?

A: LDA is intended for long-term use, and official patient information warns against abrupt discontinuation. Guidance reflecting regulatory warnings advises that suddenly stopping LDA therapy may be associated with an increased risk of thrombotic events, which are related to blood clots. Changes to the therapeutic regimen are typically discussed with a healthcare professional.


Q: Does LDA interact with birth control pills?

A: Specific combination oral contraceptives that contain the ingredient drospirenone are documented to have a potential interaction with LDA that may increase potassium levels, especially in individuals with existing risk factors. Always disclose all medications, including contraceptives, to your healthcare team.


Q: Can I consume alcohol while I am taking LDA?

A: Consumption of alcohol is noted to increase the risk of gastrointestinal bleeding when taking LDA. Official patient material describes the need to limit daily alcohol intake while using this medication to avoid this increased risk.


Q: How does LDA affect my sleep?

A: Official documentation for LDA does not commonly list sleep disturbance or insomnia as a frequently reported adverse reaction. Research has been conducted in specific patient populations regarding the drug's influence on nocturnal pain and sleep quality.


Q: Can LDA cause mood changes or irritability?

A: Mood changes or irritability are not typically listed as common adverse effects in official safety summaries. However, symptoms such as restlessness, confusion, and heightened irritability have been documented as potential signs of serious toxicity or overdose and require medical attention.


Q: How can I tell the difference between a minor side effect and an allergic reaction to LDA?

A: Official patient information distinguishes between minor side effects, such as mild stomach upset or bruising, and a severe allergic reaction (hypersensitivity). An allergic reaction is critical and may include symptoms like facial swelling, hives, or difficulty breathing, which requires immediate medical attention.


Q: What information should I know about LDA and caffeine?

A: The active ingredient in LDA is co-formulated with caffeine in some over-the-counter products, which have specific warnings regarding their combined use. For LDA alone, caffeine is not commonly listed in official labeling as a high-risk interaction that alters drug exposure.


Q: What does the research evidence say about the long-term use of LDA?

A: Long-term, daily use of LDA is a common strategy for approved uses. Official patient guidance describes its use as balancing the benefit of preventing blood clots against the risk of serious bleeding events, particularly in the gastrointestinal tract and brain, over time.


Q: What happens if I take LDA for a condition it is not approved to treat?

A: Use of LDA for any condition outside of the officially approved indications is considered off-label use. The regulatory status, including the documented safety and efficacy profile, applies only to the indications (uses) for which the medicine has received formal regulatory approval.


Q: Is LDA used to treat anything other than the main condition listed in official documents?

A: The official label and regulatory documents only describe the specific therapeutic use(s) for which the medicine has received approval. Use for other conditions is not formally evaluated by regulators and may be considered off-label.


Q: Does LDA have a generic version available yet?

A: Yes. The active ingredient in LDA is Acetylsalicylic Acid (ASA), which is itself the universally recognized generic name for the substance. LDA is frequently sold over the counter as a generic product.


Q: Is LDA a controlled substance?

A: No. LDA (Aspirin/ASA) is typically available as an over-the-counter (OTC) medicine in low doses. It is not classified as a controlled substance by the US DEA or similar regulatory bodies.


Q: If LDA isn't working for me right away, how long should I keep taking it before seeing a doctor?

A: The intended use of LDA is typically long-term for prevention. If there are questions about the medication's effect or if existing symptoms worsen or persist, official advice is to consult a healthcare professional. Official patient advice recommends that adjustments to medication use are made after consultation with a healthcare professional.


Q: Are the side effects of LDA usually temporary or do they last a long time?

A: Regulatory information indicates that many common side effects, such as minor stomach upset, may be temporary. In contrast, more serious adverse reactions like signs of internal bleeding or severe changes require immediate medical attention because they may be persistent or severe.


Q: What is the most serious side effect of LDA that I should be aware of?

A: The most serious risks highlighted in regulatory warnings are severe gastrointestinal bleeding (ulcers) and hemorrhagic stroke, which is a type of stroke caused by bleeding in the brain. These are documented in the official Warnings and Precautions sections.


Q: Does taking LDA affect my ability to drive or operate machinery?

A: LDA is not specifically documented to cause severe impairment. However, official regulatory guidance advises caution when driving or operating machinery until the user knows how their body reacts to the medicine, due to the potential for certain nervous system side effects.


Q: Are there any vitamins or herbal supplements that interact with LDA?

A: Yes. Official patient information advises that LDA may interact with certain vitamins, supplements, and herbal remedies. These interactions could potentially alter the effect of the medicine or increase the risk of side effects like bleeding. A healthcare professional should be informed of all supplements being taken.


Q: Is it necessary to have special monitoring or lab tests while taking LDA?

A: For most patients, routine lab tests may not be required for the long-term use of LDA. However, specialized functional tests may be used in specific clinical situations, such as before a scheduled surgical procedure, to measure the antiplatelet effect.


Q: Are there any specific foods or drinks I should avoid while taking LDA?

A: Consumption of alcohol is specifically warned against due to the increased risk of bleeding. Official labeling does not generally document other common foods or non-alcoholic drinks as having a systemic interaction that necessitates avoidance.


Q: How does LDA work on the body compared to a placebo?

A: Clinical trials comparing LDA with a placebo (an inactive substance) have consistently shown that LDA is associated with a reduction in the risk of serious vascular events, such as heart attack or stroke.


Q: Is LDA a good long-term solution, or is it typically a short-term treatment?

A: LDA is intended for use as a long-term maintenance treatment for approved indications. While higher doses may be used briefly for initial treatment in acute settings, the low-dose regimen is designed for sustained use.


Q: Can I take LDA if I have diabetes?

A: Diabetes is often a factor considered when a healthcare provider discusses the use of LDA, particularly for the primary prevention of cardiovascular events. Its use in this population is determined by an individual's overall risk profile.


Q: Are there different strengths of LDA available?

A: Yes. LDA is marketed in different strengths. Common doses for long-term use are the 75 mg and 81 mg maintenance doses, with other strengths sometimes used for the initial loading dose in acute settings.


Q: What is the difference between the brand name and the generic version of LDA?

A: Brand-name LDA products contain the exact same active ingredient, Acetylsalicylic Acid (ASA), as the generic versions. The key differences lie in the specific inactive ingredients and the manufacturer's formulation, such as the use of an enteric coating.


Q: What is the likelihood of having a rare, severe side effect from LDA?

A: The likelihood of rare or severe side effects is described using regulatory frequency classifications (e.g., uncommon: ge 1 in 1,000 to < 1 in 100). These classifications report the incidence rate based on the data collected during clinical trials.


Q: What are the typical reasons why a doctor would stop prescribing LDA?

A: A healthcare professional may advise stopping LDA use if a patient develops an absolute contraindication, such as an active bleeding disorder, or if the drug is deemed unnecessary based on their individual risk assessment. Temporary discontinuation is also required before some surgeries.


How should LDA be stored and disposed of?

How to Store and Dispose of Low-Dose Aspirin (LDA)

The storage and disposal of LDA must strictly adhere to regulatory labeling to maintain its stability and prevent accidental poisoning. These rules are non-negotiable and based on government guidance.

Official Storage Requirements

Condition Requirement
Temperature Do not store above 25 C (Store below 77 F).
Container Must be kept in the original container and tightly closed.
Protection Store away from moisture to protect the tablets.
Safety Must be kept out of the sight and reach of children.

Official Disposal Protocol

To discard unused or expired LDA, do not flush the medication. The preferred method is using a drug take-back program. If this is unavailable, mix the tablets with an undesirable substance (like coffee grounds), seal the mixture, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of LDA found in:

A-Z Index: